PLoS ONE volume 9, issue 6, Pe98370 2014 DOI: 10.1371/journal.pone.0098370 View full text
Ritu Arora, Clayton Yates, Bernard D. Gary, Steven McClellan, Ming Tan, Yaguang Xi, Eddie Reed, Gary A. Piazza, Laurie B. Owen, Windy Dean-Colomb

Abstract: BackgroundTriple-negative breast cancer (TNBC) is a highly diverse group that is associated with an aggressive phenotype. Its treatment has been challenging due to its heterogeneity and absence of well-defined molecular targets. Thus, there is an urgent need to identify novel agents with therapeutic application. NF-κB is over-expressed in many breast cancers; thus, inactivation of the NF-κB pathway could serve as a therapeutic target. Here we report for the first time the anti-tumor activity of panepoxydone (P…

expand abstract